The role of autoimmunity in thromboangiitis obliterans (Buerger's disease)

Annals of the New York Academy of Sciences

Volumn 1285, Issue 1, 2013, Pages 15-25

  Ketha, Siva S ^a   Cooper, Leslie T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Buerger's disease; Peripheral arterial disease; Thromboangiitis obliterans

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINUCLEAR ANTIBODY; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CD14 ANTIGEN; CD20 ANTIGEN; CD4 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; DNA FRAGMENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HLA DPB1 ANTIGEN; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; ILOPROST; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; PROSTANOID; PROTEIN S 100; PROTHROMBIN; SILDENAFIL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; AUTOIMMUNITY; BLOOD VESSEL WALL; BUERGER DISEASE; BYPASS SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CRITICAL LIMB ISCHEMIA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; ENDOTHELIUM CELL; GENETIC SCREENING; GIANT CELL; HEREDITY; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; INTIMA; LEUKOCYTE ADHERENCE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PERIODONTAL DISEASE; PROMOTER REGION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SMOKING; SMOKING CESSATION; TARGET CELL; THROMBOCYTE ADHESION; THROMBOPHILIA; ULCER; VASCULAR ENDOTHELIUM; VASCULAR LESION; VASCULAR TISSUE;

EID: 84878195861     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12048     Document Type: Article

References (81)

1. Von Winiwarter, F. 1879. Ueber eine eigenthumliche from von endarteritis und endophlephitis mit gangran des fusses. Arch. Klin. Chir. 23: 202-226.
2. Buerger 1908. Thrombo-angiits obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. Am. J. Med. Sci. 136: 567-580.
3. Wessler, S., S.C. Ming, V. Gurewich & D.G. Freiman 1960. A critical evaluation of thromboangitis obliterans. The case against Buerger's disease. N. Engl. J. Med. 262: 1149-1160 (in English).
4. McKusick, V.A. 1962. Buerger's disease: a distinct clinical and pathologic entity. JAMA 181: 5-12.
5. McPherson, J.R., J.L. Juergens & R.W. Gifford Jr. 1963. Thromboangiitis obliterans and arteriosclerosis obliterans. Clinical and prognostic differences. Ann. Intern. Med. 59: 288-296 (in English).
6. Olin, J.W. 2000. Thromboangiitis obliterans (Buerger's disease). N. Engl. J. Med. 343: 864-869 (in English).
7. Kim, E.J., B.S. Cho, et al. 2000. Morphologic change of the internal elastic lamina in Buerger's disease. J. Korean Med. Sci. 15: 44-48 (in English).
8. Gulati, S.M., K. Madhra, T.K. Thusoo, et al. 1982. Autoantibodies in thromboangiitis obliterans (Buerger's disease). Angiology 33: 642-651 (in English).
9. Berlit, P., C. Kessler, R. Reuther & K.H. Krause 1984. New aspects of thromboangiitis obliterans (von Winiwarter-Buerger's disease). Eur. Neurol. 23: 394-399 (in English).
10. Adar, R. et al. 1983. Cellular sensitivity to collagen in thromboangiitis obliterans. N. Engl. J. Med. 308: 1113-1116 (in English).
11. Hada, M., T. Sakihama, K. Kamiya, et al. 1993. Cellular and humoral immune responses to vascular components in thromboangiitis obliterans. Angiology 44: 533-540 (in English).
12. Kobayashi, M., M. Ito, A. Nakagawa, N. Nishikimi & Y. Nimura 1999. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J. Vasc. Surg. 29:451-458 (in English).
13. Mills, J.L., Sr. 2003. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. Semin. Vasc. Surg. 16: 179-189 (in English).
14. Avcu, F. et al. 2000. The role of prothrombotic mutations in patients with Buerger's disease. Thromb. Res. 100: 143-147 (in English).
15. Halacheva, K., M.V. Gulubova, I. Manolova & D. Petkov 2002. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta. Histochem. 104: 177-184 (in English).
16. Eichhorn, J. et al. 1998. Antiendothelial cell antibodies in thromboangiitis obliterans. Am. J. Med. Sci. 315: 17-23 (in English).
17. Schellong, S.M., A. Rautmann, W.L. Gross & K. Alexander 1993. No ANCA in thromboangiitis obliterans (Burger's disease). Adv. Exp. Med. Biol. 336: 327-330 (in English).
18. Halacheva, K.S., I.M. Manolova, D.P. Petkov & A.P. Andreev 1998. Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangiitis obliterans (Buerger's disease). Scand. J. Immunol. 48: 544-550 (in English).
19. Dellalibera-Joviliano, R., E.E. Joviliano, J.S. Silva & P.R.B. Evora 2012. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin. Exp. Immunol. 170: 28-35 (in English).
20. Lie, J.T. 1989. The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease). Acta. Pathol. Jpn. 39: 153-158 (in English).
21. Grove, W.J. & G.P. Stansby 1992. Buerger's disease and cigarette smoking in Bangladesh. Ann. R. Coll. Surg. Engl. 74: 115-117; discussion 118 (in English).
22. McLoughlin, G.A., C.R. Helsby, et al. 1976. Association of HLA-A9 and HLA-B5 with Buerger's disease. Br. Med. J. 2: 1165-1166 (in English).
23. Otawa, T., T. Jugi, N. Kawano, et al. 1974. Letter: HL-A antigens in thromboangiitis obliterans. JAMA 230:1128 (in English).
24. Chen, Z. et al. 2007. Synergistic contribution of CD14 and HLA loci in the susceptibility to Buerger disease. Hum. Genet. 122: 367-372 (in English).
25. Adiguzel, Y., E. Yilmaz & N. Akar 2010. Effect of eNOS and ET-1 polymorphisms in thromboangiitis obliterans. Clin. Appl. Thromb. Hemost. 16: 103-106 (in English).
26. Chen, Z. et al. 2011. A single nucleotide polymorphism in the 3'-untranslated region of MyD88 gene is associated with Buerger disease but not with Takayasu arteritis in Japanese. J. Hum. Genet. 56: 545-547 (in English).
27. Sopori, M. 2002. Effects of cigarette smoke on the immune system. Nat. Rev. Immunol. 2: 372-377 (in English).
28. Holt, P.G. & D. Keast 1977. Environmentally induced changes in immunological function: acute and chronic effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental animals. Bacteriol. Rev. 41: 205-216 (in English).
29. Geng, Y., S.M. Savage, S. Razani-Boroujerdi & M.L. Sopori 1996. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. J. Immunol. 156: 2384-2390 (in English).
30. Silverstein, P. 1992. Smoking and wound healing. Am. J. Med. 93: 22S-24S (in English).
31. Gairola, C.G. 1986. Free lung cell response of mice and rats to mainstream cigarette smoke exposure. Toxicol. Appl. Pharmacol. 84: 567-575 (in English).
32. Ludwig, P.W., B.A. Schwartz, J.R. Hoidal & D.E. Niewoehner 1985. Cigarette smoking causes accumulation of polymorphonuclear leukocytes in alveolar septum. Am. Rev. Respir. Dis. 131: 828-830 (in English).
33. MacNee, W., B. Wiggs, A.S. Belzberg & J.C. Hogg 1989. The effect of cigarette smoking on neutrophil kinetics in human lungs. N. Engl. J. Med. 321: 924-928 (in English).
34. Lehr, H.A. 1993. Adhesion-promoting effects of cigarette smoke on leukocytes and endothelial cells. Ann. N.Y. Acad. Sci. 686: 112-118; discussion 118-119 (in English).
35. van der Vaart, H., D.S. Postma, W. Timens & N.H. ten Hacken 2004. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 59: 713-721 (in English).
36. Morrison, D., I. Rahman, S. Lannan & MacNee W. 1999. Epithelial permeability, inflammation, and oxidant stress in the air spaces of smokers. Am. J. Respir. Crit. Care Med. 159: 473-479 (in English).
37. Dhami, R. et al. 2000. Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Am. J. Respir. Cell. Mol. Biol. 22: 244-252 (in English).
38. Churg, A. et al. 2002. Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am. J. Respir. Cell. Mol. Biol. 27: 368-374 (in English).
39. Bhalla, D.K., F. Hirata, A.K. Rishi & C.G. Gairola 2009. Cigarette smoke, inflammation, and lung injury: a mechanistic perspective. J. Toxicol. Environ. Health B Crit. Rev. 12: 45-64 (in English).
40. Newby, D.E. et al. 1999. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99: 1411-1415 (in English).
41. Fusegawa, Y., S. Goto, S. Handa, et al. 1999. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb. Res. 93: 271-278 (in English).
42. Matetzky, S. et al. 2000. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 102: 602-604 (in English).
43. Nowak, J., J.J. Murray, J.A. Oates & G.A. FitzGerald 1987. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 76: 6-14 (in English).
44. Leone, A. 2005. Biochemical markers of cardiovascular damage from tobacco smoke. Curr. Pharm. Des. 11: 2199-2208.
45. Iwai, T. et al. 2005. Oral bacteria in the occluded arteries of patients with Buerger disease. J. Vasc. Surg. 42: 107-115 (in English).
46. Chen, Y.W. et al. 2009. Association between periodontitis and anti-cardiolipin antibodies in Buerger disease. J. Clin. Periodontol. 36: 830-835 (in English).
47. Mills, J.L. & J.M. Porter 1993. Buerger's disease: a review and update. Semin. Vasc. Surg. 6: 14-23 (in English).
48. Papa, M.Z., I. Rabi & R. Adar 1996. A point scoring system for the clinical diagnosis of Buerger's disease. Eur. J. Vasc. Endovasc. Surg. 11: 335-339 (in English).
49. Shionoya, S. 1998. Diagnostic criteria of Buerger's disease. Int. J. Cardiol. 66 Suppl 1: S243-S245; discussion S247 (in English).
50. Olin, J.W. & A. Shih 2006. Thromboangiitis obliterans (Buerger's disease). Curr. Opin. Rheumatol. 18: 18-24 (in English).
51. Maslowski, L., R. McBane, P. Alexewicz & W.E. Wysokinski 2002. Antiphospholipid antibodies in thromboangiitis obliterans. Vasc. Med. 7: 259-264 (in English).
52. Ansari, A. 1990. Thromboangiitis obliterans: current perspectives and future directions. Tex. Heart Inst. J. 17: 112-117 (in English).
53. Arkkila, P.E. 2006. Thromboangiitis obliterans (Buerger's disease). Orphanet. J. Rare. Dis. 1: 14 (in English).
54. Mills, J.L., L.M. Taylor, Jr. & J.M. Porter 1987. Buerger's disease in the modern era. Am. J. Surg. 154: 123-129 (in English).
55. Sasaki, S., M. Sakuma, T. Kunihara & K. Yasuda 1999. Current trends in thromboangiitis obliterans (Buerger's disease) in women. Am. J. Surg. 177: 316-320 (in English).
56. Cooper, L.T. et al. 2004. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). J. Am. Coll. Cardiol. 44: 2410-2411 (in English).
57. Ohta, T., H. Ishioashi, M. Hosaka & I. Sugimoto 2004. Clinical and social consequences of Buerger disease. J. Vasc. Surg. 39: 176-180 (in English).
58. Olin, J.W., J.R. Young, R.A. Graor, W.F. Ruschhaupt & J.R. Bartholomew 1990. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 82(5 Suppl): IV3-8 (in English).
59. Dargon, P.T. & G.J. Landry 2012. Buerger's disease. Ann. Vasc. Surg. 26: 871-880 (in English).
60. Corelli, F. 1973. Buerger's disease: cigarette smoker disease may always be cured by medical therapy alone. Uselessness of operative treatment. J. Cardiovasc. Surg. 14: 28-36 (in English).
61. Hurt, R.D. & J.T. Hays 2008. Urinary tobacco alkaloid measurement in patients having thromboangiitis obliterans. Mayo. Clin. Proc. 83: 1187-1188; author reply. 1188 (in English).
62. Cooper, L.T. et al. 2006. A prospective, case-control study of tobacco dependence in thromboangiitis obliterans (Buerger's Disease). Angiology 57: 73-78 (in English).
63. Montori, V.M., S.J. Kavros, E.E. Walsh & T.W. Rooke 2002. Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000). Int. Angiol. 21: 360-366 (in English).
64. Anonymous. 1998. Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. Eur. J. Vasc. Endovasc. Surg. 15: 300-307 (in English).
65. Fiessinger, J.N. & M. Schafer 1990. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO study. Lancet 335: 555-557 (in English).
66. Watts, S.W. 2010. Endothelin receptors: what's new and what do we need to know?Am. J. Physiol. Regul. Integr. Comp. Physiol. 298: R254-260 (in English).
67. Todoli Parra, J.A., M.M. Hernandez & M.A. Arrebola Lopez 2010. Efficacy of bosentan in digital ischemic ulcers. Ann. Vasc. Surg. 24: 690 e691-694 (in English).
68. De Haro, J., F. Acin, S. Bleda, et al. 2012. Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan. BMC Cardiovasc. Disord. 12: 5 (in English).
69. Sasajima, T., Y. Kubo, M. Inaba, K. Goh & N. Azuma 1997. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur. J. Vasc. Endovasc. Surg. 13: 186-192 (in English).
70. Isner, J.M. et al. 1998. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg. 28: 964-973; discussion 973-965 (in English).
71. Kim, H.J. et al. 2004. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp. Mol. Med. 36: 336-344 (in English).
72. Matoba, S. et al. 2008. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am. Heart J. 156: 1010-1018 (in English).
73. Saito, Y. et al. 2007. Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. Circ. J. 71: 1187-1192 (in English).
74. Durdu, S. et al. 2006. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J. Vasc. Surg. 44: 732-739 (in English).
75. Motukuru, V., K.R. Suresh, V. Vivekanand, S. Raj & K.R. Girija 2008. Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J. Vasc. Surg. 48(6 Suppl): 53S-60S; discussion 60S (in English).
76. Baumann, G. et al. 2011. Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study. Clin. Res. Cardiol. 100: 683-690 (in English).
77. Laczika, K. et al. 2000. Immunoadsorption in Goodpasture's syndrome. Am. J. Kidney. Dis. 36: 392-395 (in English).
78. Gajdos, P., S. Chevret & K. Toyka 2002. Plasma exchange for myasthenia gravis. Cochrane Database Syst. Rev. (4): CD002275 (in English)
79. Stummvoll, G.H. 2011. Immunoadsorption (IAS) for systemic lupus erythematosus. Lupus 20: 115-119 (in English).
80. Burgstaler, E.A., L.T. Cooper & J.L. Winters 2007. Treatment of chronic dilated cardiomyopathy with immunoadsorption using the staphylococcal A-agarose column: a comparison of immunoglobulin reduction using two different techniques. J. Clin. Apher. 22: 224-232 (in English).
81. Cooper, L.T. et al. 2007. A pilot study to assess the use of protein a immunoadsorption for chronic dilated cardiomyopathy. J. Clin. Apher. 22: 210-214 (in English).